Skip to main content

Want the latest news and information delivered to your inbox?

sign up here
  • Prescribing Information
  • For Healthcare Professionals
  • Select Condition:
    • Recurrent Pericarditis
    • Cryopyrin-Associated Periodic Syndromes (CAPS)
    • Deficiency of Interleukin (IL-1) Receptor Antagonist
  • PRESCRIBING INFORMATION
  • FOR HEALTHCARE PROFESSIONALS
ARCALYST Logo
  • Recurrent Pericarditis
    • Definition
    • Types of Pericarditis
    • Symptoms
    • Causes
    • Management
    • Treatment
  • Take Control
    • Why ARCALYST
    • Fewer Flares
    • Symptom Relief
    • More Pain-free Days
    • Freedom From Steroids
    • How It Works
    • Safety
  • How to Use ARCALYST
    • How to Take ARCALYST
    • FAQs
  • Kiniksa OneConnect™ Support
    • Support & Services
    • Starting Treatment
    • Financial Assistance
    • Treatment Support
  • Personal Stories
    • Real-life Experiences
  • Resources/FAQ
    • FAQs
    • Resources
  • Webinars
    • Upcoming Webinars
    • Past Webinars
  • Select Condition:
    • Recurrent Pericarditis
    • Cryopyrin-Associated Periodic Syndromes (CAPS)
    • Deficiency of Interleukin (IL-1) Receptor Antagonist
  • Recurrent Pericarditis
    • Definition
    • Types of pericarditis
    • Symptoms
    • Causes
    • Management
    • Treatment
  • Take Control
    • Why ARCALYST
    • Fewer Flares
    • Symptom Relief
    • More Pain-free Days
    • Freedom From Steroids
    • How It Works
    • Safety
  • How to Use ARCALYST
    • How to Take ARCALYST
    • FAQs
  • Kiniksa OneConnect™ Support
    • Support & Services
    • Starting Treatment
    • Financial Assistance
    • Treatment Support
  • Personal Stories
    • Real-life Experiences
  • Resources/FAQ
    • FAQs
    • Resources
  • Webinars
    • Upcoming Webinars
    • Past Webinars

Contact Us

Loading...
1 7
Take Control
2 7
How To Use
3 7
Support
4 7
Personal Stories
5 7
Resources/FAQs
6 7
Webinars
7 7
Resources/FAQs
  • Prescribing Information
  • For Healthcare Professionals
Want the latest news and information delivered to your inbox?
Sign upHere

QUICK RESOURCES

  • Image - Warren facing Camera

    Warren’s Story

    Watch Now
  • Image - ARCALYST Brochure

    ARCALYST Brochure

    Download
  • Image - Doctor Discussion Guide

    Doctor Discussion Guide

    Download

Important Safety Information

  • ARCALYST may affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection).
  • While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel® (etanercept), Humira® (adalimumab), or Remicade® (infliximab), as this may increase your risk of getting a serious infection.
  • Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST.
  • Medicines that affect the immune system may increase the risk of getting cancer.
  • Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction.
  • Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides.
  • Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose.

For more information about ARCALYST, speak with your doctor and see the full Prescribing Information.

INDICATION

ARCALYST® (rilonacept) is an interleukin-1 blocker indicated for:

  • Treatment of Recurrent Pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.
  • Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older. 
  • Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more.
Expand
  • Arcalyst Bottom logo
  • Kiniksa Logo

This site is intended for US audiences only.

ARCALYST is a registered trademark of Regeneron Pharmaceuticals, Inc. All other trademarks and registered trademarks are the property of their respective owners. Kiniksa OneConnect is a trademark of Kiniksa Pharmaceuticals.

© 2023 Kiniksa Pharmaceuticals (UK), Ltd. All Rights Reserved. 03/23 ARC-US-00056-23

Patient Footer Navigation

  • Terms of Use
  • Privacy Policy
  • Contact Us
Go Back Continue